Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that chronic telogen effluvium in middle-aged women presents distinct clinical and histological features that differ from androgenetic alopecia and acute telogen effluvium.

This correspondence outlines a research aim to evaluate the usefulness of laboratory testing for telogen effluvium to assist in forming evidence-based treatment guidelines, though results are not provided in the abstract.

This exploratory pilot study reported that using a 2% Oleosome-FGF-2 fusion extract scalp serum twice daily for 84 days in women with telogen effluvium and brittle hair improved hair density, anagen/telogen ratio, hair shaft thickness, and scalp hydration compared to a placebo.

This article reviews the concept of telogen effluvium and emphasizes the importance of identifying triggers and using diagnostic investigations to determine the cause of hair loss, without reporting new results.

In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.

This review discusses telogen effluvium, including its triggers, clinical presentations, and management options, and does not report new research findings, emphasizing the need for identification and exclusion of underlying causes.

This case study reports that localized telogen effluvium may be a cause of hair loss following hair transplantation, based on observations in two patients with diffuse hair shedding primarily in the frontal and temporal scalp areas.

This study found that oxidative stress, measured through thiol/disulfide balance, is closely linked to the pathogenesis of telogen effluvium.

This article discusses telogen effluvium, emphasizing the importance of understanding its natural progression and highlights the need for a detailed patient evaluation but provides no new clinical results.

This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.

This study found that mice lacking the type 3 IP(3) receptor in their hair follicles experienced repetitive hair loss and regrowth, indicating disrupted hair-cycle regulation potentially linked to specific signaling pathways.

This review discusses telogen effluvium as a common cause of diffuse hair loss and reports no new clinical results, noting diagnostic and treatment challenges.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

A vitamin and mineral supplement significantly reduced hair shedding in Brazilian women with telogen effluvium.

This essay discusses telogen effluvium, the issues surrounding its diagnosis and differentiation from other forms of hair loss, and emphasizes the need for empathetic patient care; it reports no new clinical findings.

COVID-19 and related stress may increase hair loss known as Telogen effluvium.

This study found that a refined wash test can effectively differentiate shedding hair characteristics among normal individuals, and patients with androgenetic alopecia or telogen effluvium, aiding in diagnosis and monitoring.

In this case report, a middle-aged female patient experienced significant improvement in chronic telogen effluvium symptoms, including reduced hair fall and improved hair density, following an individualized homeopathic treatment at Dr. Batra’s, highlighting the role of addressing emotional, metabolic, and nutritional factors.

In this study, a Monte Carlo-generated synthetic cohort analysis found that higher simulated cannabis exposure was linked to increased self-assessed hair loss severity and reduced follicular density, suggesting potential connections worth exploring in further clinical research.

Oral Vitamin D can improve hair density and reduce hair loss in Telogen Effluvium patients.

This review discusses telogen effluvium, its causes, and diagnostic methods, but reports no new clinical results; the authors emphasize the importance of patient education on the condition's progression.

This review examines chronic telogen effluvium, highlighting its distinctive features and the need for reassurance about its non-progressive nature, but reports no new clinical results.

COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.

This study introduces the concept of teloptosis, which influences hair shedding during the telogen phase and affects hair density, highlighting that early or delayed teloptosis has noticeable effects.

This review discusses various techniques for evaluating hair shedding and alopecia but reports no new clinical results. The authors emphasize the value of specific clinical and instrumental methods in assessing hair growth.

This study suggests that COVID-19 infection may trigger telogen effluvium, a condition of hair shedding, though medication side effects and pandemic-related stress cannot be excluded as contributing factors.

This study found that 1% ketoconazole and 1% piroctone olamine shampoos increased hair shaft thickness and reduced hair shedding in men with telogen effluvium and androgenic alopecia associated with dandruff.

This study reports that hair growth and shedding in healthy women show annual seasonal patterns, with the highest shedding in summer and a less pronounced peak in spring.

This paper highlights trichodynia as a distinguishing symptom of telogen effluvium, but it does not present new clinical findings.

This study found that a 1% Sandalore® solution reduced hair shedding and improved hair volume and anagen phase duration in women with telogen effluvium over 24 weeks, compared to placebo.